My working hypothesis is that IBS is somatisation of mental illness. That could be why the placebo has an effect for it. It’s all in the head to start with. Mental illness and IBS are associated.
Research into the neurological basis of the placebo response was launched by the discovery that placebo-induced analgesia could be blocked by the opioid antagonist naloxone [8]. Today there is converging evidence that opioid receptors and dopamine-reward circuitry form part of the neurological placebo-response pathway [9,10]. With potential mechanisms in sight, the search for genetic bio-markers of placebo response is now a feasible proposition. We recently provided evidence that COMT, an enzyme that plays a key role in prefrontal and mid-brain dopamine tuning, may be a biomarker of placebo response in irritable bowel syndrome [11]
“COMT made for an excellent candidate because it’s been implicated in the cause and treatment of many conditions, including pain and Parkinson’s disease,” says Hall. “It’s also been found in behavioral genetic models of reward responsiveness and confirmation bias, the tendency to confirm new information based on your beliefs.”
My working hypothesis is that IBS is somatisation of mental illness. That could be why the placebo has an effect for it. It’s all in the head to start with. Mental illness and IBS are associated.